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Abstract
Background: Emerging studies have demonstrated that pretreatment with electroacupuncture (EA) induces
significant tolerance to focal cerebral ischemia. The present study seeks to determine the involvement of monocyte
chemotactic protein-induced protein 1 (MCPIP1), a recently identified novel modulator of inflammatory reactions, in
the cerebral neuroprotection conferred by EA pretreatment in the animal model of focal cerebral ischemia and to
elucidate the mechanisms of EA pretreatment-induced ischemic brain tolerance.
Methods: Twenty-four hours after the end of the last EA pretreatment, focal cerebral ischemia was induced by
middle cerebral artery occlusion (MCAO) for 90 minutes in male C57BL/6 mice and MCPIP1 knockout mice.
Transcription and expression of MCPIP1 gene was monitored by qRT-PCR, Western blot and immunohistochemistry.
The neurobehavioral scores, infarction volumes, proinflammatory cytokines and leukocyte infiltration in brain and
NF-κB signaling were evaluated after ischemia/reperfusion.
Results: MCPIP1 protein and mRNA levels significantly increased specifically in mouse brain undergoing EA
pretreatment. EA pretreatment significantly attenuated the infarct volume, neurological deficits, upregulation of
proinflammatory cytokines and leukocyte infiltration in the brain of wild-type mice after MCAO compared with that
of the non-EA group. MCPIP1-deficient mice failed to evoke EA pretreatment-induced tolerance compared with that
of the control MCPIP1 knockout group without EA treatment. Furthermore, the activation of NF-κB signaling was
significantly reduced in EA-pretreated wild-type mice after MCAO compared to that of the non-EA control group
and MCPIP1-deficient mice failed to confer the EA pretreatment-induced inhibition of NF-κB signaling after MCAO.
Conclusions: Our data demonstrated that MCPIP1 deficiency caused significant lack of EA pretreatment-induced
cerebral protective effects after MCAO compared with the control group and that MCPIP1 is involved in EA
pretreatment-induced delayed brain ischemia tolerance.
Keywords: Ischemic stroke, Electroacupuncture, Monocyte chemotactic protein-induced protein 1 (MCPIP1), Middle
cerebral artery occlusion (MCAO), Proinflammatory cytokines
Background
Stroke is the second leading cause of death and the most
frequent cause of permanent disability worldwide [1]. In
recent investigation, it is reported that stroke strikes
approximately 800,000 people per year in the United
States alone, killing about 150,000 [2,3]. Ischemic strokes
are more prevalent than hemorrhagic. Thrombosis, an
embolism or systemic hypoperfusion can cause an ische-
mic stroke. Within the core of the ischemic brain, where
blood flow is most severely restricted, excitotoxic and
necrotic cell death occurs within minutes. In the periph-
ery of the ischemic area, where collateral blood flow can
buffer the full effects of the stroke, ischemic brain
damage happens within hours to days post stroke via
mechanisms such as apoptosis and inflammation [4,5].
Inflammatory mechanisms that are activated within
hours after brain ischemia represent a key target of
current translational ischemic stroke research [6]. It has
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been reported that the levels of proinflammatory cyto-
kines and chemokines increased after focal ischemia.
Chemokines are cytokines that have the ability to induce
chemotaxis on neighboring cells, particularly those in-
volved in inflammatory actions [7]. While some cyto-
kines may offer protection, many cytokines and most
chemokines have been shown to participate in the neur-
onal damage processes [8,9].
A brief exposure to sublethal or noninjurious stimuli
renders the brain resistant to a subsequent damaging is-
chemic insult. Ischemic tolerance consists of an early
phase that occurs within minutes after induction,
followed by a delayed phase that develops many hours
or even days later. Delayed preconditioning has gener-
ated much interest because it produces a potent
neuroprotection whose mechanisms may suggest new
treatments for ischemic stroke [10]. Published data have
shown recently that electroacupuncture (EA) pretreat-
ment has such a neuroprotective effect [11-17]. EA
pretreatment-induced neuroprotection or bioprotection
is related to the suppression of the inflammatory re-
sponse in the ischemic or injured area, but the mecha-
nisms involved in the protection afforded by EA
pretreatment are poorly understood [18-21].
Monocyte chemotactic protein-induced protein 1
(MCPIP1, also known as ZC3H12A) is a recently identi-
fied protein in human peripheral blood monocytes
treated with monocyte chemotactic protein-1 (MCP-1)
[22]. In our previous studies, MCPIP1 was shown to be
a negative regulator of macrophage activation [23]. Fur-
ther investigations by our group and others indicated
that MCPIP1 can play a significant anti-inflammatory
role by inhibiting the generation of a set of major
proinflammatory cytokines [24,25]. In our previous stud-
ies, MCPIP1 was also found to be inducibly expressed in
monocytes, macrophages, and endothelial cells with
lipopolysaccharide (LPS) stimulation [26,27] and partici-
pates in LPS preconditioning-induced ischemic brain
tolerance [28]. The present study examined the effects
of EA pretreatment at the Baihui acupoint on MCAO-
induced cerebral inflammatory response and ischemic
brain injury in wild-type and MCPIP1 knockout mice.
Methods
Animals
MCPIP1 knockout mice were established as previously
described [24]. Briefly, Mcpip1−/− mice were generated
by homologous recombination in embryonic stem cells
from C57/BL6 background mice. Exons 3, 4, 5 and most
part of 6 of mouse Mcpip1 were targeted with a LacZ-
neomycin cassette in embryonic stem cells established
from C57/BL6 mice and established Mcpip1−/− mice in
pure C57/BL6 background. The absence of MCPIP1
protein in Mcpip−/− mice was confirmed by immu-
noblotting. Six to eight-week-old mice were used. All
experimental procedures were approved by the Institu-
tional Animal Care and Use Committee of the University
of Central Florida. We performed all the experiments by
using littermate mice.
Electroacupuncture pretreatment
The experimental protocol is shown in Figure 1. EA pre-
treatment was performed following a modification of
the method reported by Wang and colleagues [15,29] at
the acupoint ‘Baihui (GV 20)’, which is located at the
intersection of the sagittal midline and the line linking
the two ears. Briefly, animals were anesthetized with
isoflurane (induction with 3%; maintenance with 1.2%)
in oxygen-enriched air by face mask, and rectal
temperature was controlled at 37 ± 0.5°C throughout
the experiment with heating lamps. The acupoint ‘Baihui
(GV 20)’ was stimulated at an intensity of 1 mA and a
frequency of 2/15 Hz for 30 min, using the Hwato Elec-
tronic Acupuncture Treatment Instrument (Model No.
SDZ-V, Suzhou Medical Appliances Co., Ltd., Suzhou,
China). The animals received daily EA preconditioning
for two consecutive days, and were subjected to MCAO
24 h after the end of the last EA pretreatment. The mice
in the control group underwent the same procedures as
the EA group without the electroacupuncture. All
electroacupuncture experimental procedures were ap-
proved by the Institutional Animal Care and Use Com-
mittee of the University of Central Florida. Protocol
number is 10-31 (2012).
Mice focal brain ischemia reperfusion model
For focal brain ischemia, mouse transient middle cere-
bral artery occlusion (MCAO) was produced by filament
occlusion of the right MCA as previously described [28].
In brief, mice were anesthetized with isoflurane (induc-
tion with 3%; maintenance with 1.2%) in oxygen-
enriched air by face mask, and rectal temperature was
controlled at 37 ± 0.5°C throughout the experiment with
heating lamps. Unilateral MCAO was performed by
inserting a 7–0 nylon monofilament into the internal
carotid artery via an external carotid artery stump and
then positioning the filament tip for occlusion at a
distance of 8 to 9 mm beyond the internal carotid/
pterygopalatine artery bifurcation. MCA was occluded
for 90 min followed by reperfusion.
Brain infarction measurement
The brains were stained with 2,3,5-triphenyltetrazolium
chloride (TTC) (Sigma-Aldrich, St Louis, MO, USA) to
determine infarct volume [28]. After 90 min of MCAO
and 48 h of reperfusion, mice were anesthetized with 4%
isoflurane and brains were removed and sectioned
coronally at a thickness of 2 mm and incubated in 2%
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TTC at 37°C for 20 min. Brain slices were then fixed in
4% paraformaldehyde at 4°C overnight and scanned into
a computer, and quantified using the Image J software
(NIH, Bethesda, MD, USA). Infarct volume was
expressed as a percentage of the contralateral hemi-
sphere. There were 10 mice in each group.
Neurological function assessment
The functional outcome of the animals were assessed at
48 h after ischemic/reperfusion. A modified Bederson
score [30,31] was determined according to the following
scoring system: 0, no deficit; 1, forelimb flexion; 2, as for
1, plus decreased resistance to lateral push; 3, unidirec-
tional circling; 4, longitudinal spinning or seizure activ-
ity; 5, no movement. Twenty-four hours and 48 h after
surgery, the foot fault test and grip test were performed.
The grip test, also known as the string test, was adapted
from a published report [32], with a modified scoring
system. For this test, the mouse was placed midway on a
string between two supports and rated as follows: 0, falls
off; 1, hangs onto string by one or both forepaws; 2, as
for 1, and attempts to climb onto string; 3, hangs onto
string by one or both forepaws plus one or both hind
paws; 4, hangs onto string by fore- and hind paws plus
tail wrapped around string; 5, escape (to the supports).
Quantitative real-time PCR
Quantitative real-time polymerase chain reaction (qRT-
PCR) was performed as previously described [29].
Briefly, total RNA was isolated using RNA STAT-60
reagent (Tel-Test, Inc., Friendswood, TX, USA), after re-
moving the genomic DNA using DNase I (Ambion,
Austin, TX, USA), 2.0 ug of total RNA from microglia or
mouse brain tissue was reverse-transcribed to cDNA
using a commercially available kit (Applied Biosystems,
Foster City, CA, USA). qRT-PCR was performed with an
iCycler Thermal Cycler (Bio-Rad, Hercules, CA, USA)
using 2 × SYBR Green master mixes (Bio-Rad). Forty
cycles were conducted as follows: 95°C for 30s, 60°C for
30s, proceeded by 10 min at 95°C for polymerase
activation. Quantification was performed by the delta
cycle time method, with mouse β-actin used for
Figure 1 Diagram of experimental protocol. Non-EA, animals received no EA treatment but isoflurane inhalation the same as the EA group;
EA, preconditioning with EA for 30 min daily for two consecutive days before MCAO. EA, electroacupuncture; MCAO, middle cerebral
artery occlusion.
Figure 2 EA treatment induced MCPIP1 in the brain. (A) MCPIP1 mRNA expression in mouse brain by EA treatment as measured by qRT-PCR.
Values represent mean ± SD, *P <0.05, #P <0.01, §P <0.001 versus control. (B) MCPIP1 protein levels in mouse brain by EA treatment as measured
by Western blot. Results are representative of three independent experiments. *P <0.05 versus control. (C) MCPIP1 mRNA expression in mouse
heart by EA treatment as measured by qRT-PCR. Values represent mean ± SD. (D) MCPIP1 mRNA expression in mouse liver by EA treatment as
measured by qRT-PCR. Values represent mean ± SD. EA, electroacupuncture; MCPIP1, monocyte chemotactic protein-induced protein 1; qRT-PCR,
quantitative real-time polymerase chain reaction; SD, standard deviation.
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normalization. Human MCPIP1 gene-specific primers
(Integrated DNA Technologies, Coralville, IA, USA)
were F: 5´-GCCGGCGGCCTTA; R: 5´-GCACTGCTCA
CTCTCTGTTAGCA. The mouse-specific primers (Inte-
grated DNA Technologies) are as follows, MCPIP1: F:
5’-CCCCCTGACGACCCTTTAG; R: 5’ GGCAGTG
GTTTCTTACGAAGGA, tumor necrosis factor-alpha
(TNF-α): F: 5’- CTGAGGTCAATCTGCCCAAGTAC; R:
5’-CTTCACAGAGCAATGACTCCAAAG, interleukin-1
beta (IL-1β): F: 5’- GCCCATCCTCTGTGACTCAT; R:
5’- AGGCCACAGGTATTTTGTCG, IL-6: F: 5’- TCGT
GGAAATGAGAAAAGAGTTG; R: 5’- AGTGCATCAT
CGTTGTTCATACA, MCP-1: F: 5’- CCATCTCTGAC
CTGCTCTTCCT; R: - AGACCCACTCATTTGCAGCA
T, beta-actin: F: 5’- AAATCGTGCGTGACATCAAAGA,
R: 5’- GGCCATCTCCTGCTCGAA.
Western blot
Western blot was performed as previously described
[28]. Proteins from mouse brain tissue were extracted
and concentrations were determined by the Bradford
method (Bio-Rad) with bovine serum albumin as the
standard. Proteins (50 ug) were separated by SDS-PAGE
and transferred onto nitrocellulose membranes in trans-
fer buffer containing 0.1% SDS. The membranes were
blocked with 5% nonfat dry milk in 0.05% Tween 20 in
Tris-buffered saline (TTBS) for 2 h and incubated with
the primary antibodies against MCPIP1 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), phosphor-p65
(Cell Signaling Technology, Danvers, MA, USA), p65
(Cell Signaling Technology) at a 1:1000 dilution in the
blocking buffer, 4°C, gently shaking, overnight. After be-
ing washed with TTBS three times for 10 min each, the
Figure 3 MCPIP1 is expressed in neurons and astrocytes. Co-localization of MCPIP1 expression of (a) NSE, (d) GFAP, and (g) CD11b at 24 h
after the end of the last EA pretreatment. Yellow fluorescence indicates co-localization of MCPIP1/NSE (c) and MCPIP1/GFAP (i). MCPIP1/CD11b
(f) showed very few yellow fluorescent structures. Similar results were obtained from a total of 12 mice (n = 4 per group). (Magnification 400X).
EA, electroacupuncture; GFAP, glial fibrillary acidic protein; MCPIP1, monocyte chemotactic protein-induced protein 1; NSE, neuron-specific
enolase.
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membranes were incubated with a 1:2,000 dilution of
secondary antibody (Santa Cruz Biotechnology) in TTBS
for 1 h. Following three 10-min washes with TTBS,
membranes were incubated with SuperSignal West Pico
Chemiluminescent Substrate (Thermo Scientific Pierce
Antibodies, Rockford, IL, USA) and exposed to X-ray
film. The intensity of bands was quantified by Alpha-
Imager 2200 (Alpha Innotech, San Leandro, CA, USA).
The ratios between interested protein bands and the
loading control (β-actin, total p65) were calculated and
the data are expressed as the normalized folds with
respect to sham.
Immunohistochemistry
At 48 h after reperfusion, mice were transcardially per-
fused under anesthesia with ice-cold phosphate-buffered
saline and then with 4% paraformaldehyde. Brains were
removed and fixed overnight in 4% paraformaldehyde at
4°C. The brains were sectioned coronally at 30 μm thick-
ness in ice-cold phosphate-buffered saline using a vibrat-
ing microtome (Leica Microsystems, Buffalo Grove, IL,
USA). The sections were placed in an anti-freeze solu-
tion and stored at −20°C for later use. They were
washed, the nonspecific binding sites on sections were
blocked with 3% bovine serum albumin, and incubated
overnight with primary antibody against CD45, leuko-
cyte common antigen, antibody against glial fibrillary
acidic protein (GFAP), primary antibody against CD11b
(BD Biosciences Pharmingen, San Diego, CA, USA), pri-
mary antibody against neuron-specific enolase (NSE)
(Life Technologies, Carlsbad, CA, USA), primary anti-
body against MCPIP1 (Santa Cruz Biotechnology, CA,
USA), AlexaFluor™ 488-conjugated secondary antibody
(Life Technologies) and AlexaFluor™ 594-conjugated sec-
ondary antibody (Life Technologies) and scanned under
a fluorescence microscope (Leica TCS SP5) at 400×
magnification. Three fields per section were captured
and analyzed.
Statistical analysis
The data are presented as mean ± standard deviation
(SD). Multiple comparisons were evaluated by one-way
ANOVA followed by the Tukey or Dunnett test. Two-
group comparisons were analyzed by the two-tailed
Figure 4 The expression levels of MCP-1 and MCPIP1 in brain
after EA treatment. The results showed that there were no
significant changes in the transcript levels of MCP-1 at 3 h, 6 h and
12 h after EA pretreatment and MCPIP1 mRNA levels decreased at
later time points. Values represent mean ± SD, *P <0.05, #P <0.01,
§P <0.001 versus control; n = 6 mice per group. EA, electroacupuncture;
MCPIP1, monocyte chemotactic protein-induced protein 1; SD,
standard deviation.
Figure 5 Reduction in infarct size by EA treatment in wild-type but not in MCPIP1 knockout mice. The brain infarct size was assessed 48 h
after MCAO. (A) Infarct images obtained by TTC staining at 48 h after MCAO. The normal tissue was stained deep red and the infarct was stained
milky. (B) Brain infarcts were quantified as percentage area of ischemic hemisphere. The infarct size of EA-pretreated wild-type mice was
significantly reduced compared to that of control. There was no significant difference in brain infarct size between EA-pretreated and control in
MCPIP1 knockout mice. Values represent mean ± SD, *P <0.05, n = 10 mice per group. EA, electroacupuncture; MCAO, middle cerebral artery
occlusion; MCPIP1, monocyte chemotactic protein-induced protein 1; SD, standard deviation; TTC, 2,3,5-triphenyltetrazolium chloride.
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Student t test. For all analyses, a value of P <0.05 was
considered significant.
Results
MCPIP1 induction in mouse brain by EA pretreatment
In ischemic stroke, EA pretreatment has been demon-
strated to have a significant protective effect against
brain damage, but the underlying mechanism remains
poorly understood. First, we examined whether EA
pretreatment induces MCPIP1 in mouse brain. The
MCPIP1 mRNA level in mouse cortex brain was signifi-
cantly induced by EA pretreatment compared to controls;
significant increase of MCPIP1 in transcript level was
detected at 6 h and reached 13.6- ± 2.13 fold at 12 h
after EA pretreatment (P <0.001; Figure 2A). Consist-
ently, the MCPIP1 protein levels in mouse brain were
significantly higher in EA pretreatment than in the con-
trols, 7.5- ± 0.95 fold at 48 h after EA pretreatment
(P <0.05; Figure 2B). To determine whether EA treat-
ment induces the expression of MCPIP1 systemically
after EA treatment, we measured the transcript level of
MCPIP1 in heart and liver tissue. The results showed
that there was no significant induction of MCPIP1 in
the heart (Figure 2C) and liver (Figure 2D) after EA
treatment compared with the control group. Thus, the
EA treatment we used induced MCPIP1 expression se-
lectively in the brain.
To determine the cellular localization of MCPIP1
expression, sections from mice brain at 24 h after the
end of the last EA pretreatment were subjected to im-
munohistochemistry with antibodies against MCPIP1.
MCPIP1 expression co-localized with NSE, a neuron-
Figure 6 Protection of neurological function after MCAO by EA treatment in wild-type but not in MCPIP1 knockout mice. Neurological
function assessment was performed 24 h after MCAO. The neurological scores of EA-pretreated wild-type mice were significantly improved
compared to that of control. In MCPIP1-deficient mice, there was no significant difference in neurological deficits between the EA-pretreated and
the control group. EA, electroacupuncture; MCAO, middle cerebral artery occlusion; MCPIP1, monocyte chemotactic protein-induced protein 1.
Figure 7 Reduction in inflammatory cytokine production in ischemic brain by EA treatment in wild-type but not in MCPIP1 knockout
mice. The results showed that the expression levels of TNF-α, IL-1β, IL-6 and MCP-1 were significantly elevated in shams in MCPIP1 knockout
mice than that of wild type (for example TNF-α 1 ± 0.27 versus 2.8 ± 0.35) and that the expression levels of TNF-α, IL-1β, IL-6 and MCP-1 were
significantly reduced at 24 h after MCAO in EA-pretreated wild-type mice compared to that of control. In the MCPIP1-deficient mice, there was
no significant difference in proinflammatory cytokine expression between the EA-pretreated and the control group without EA treatment. Values
represent mean ± SD, n = 6 mice per group. EA, electroacupuncture; IL-1β, interleukin-1 beta; MCAO, middle cerebral artery occlusion; MCPIP1,
monocyte chemotactic protein-induced protein 1; TNF-α, tumor necrosis factor-alpha; SD, standard deviation.
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specific marker, implying that MCPIP1 protein expres-
sion was increased in neurons after EA treatment
(Figure 3c). A co-localization study of MCPIP1 and
GFAP, a marker for activated astrocytes, showed a few
MCPIP1/GFAP positive cells (Figure 3f ). CD11b is a
leukocyte-specific receptor and is regarded as a marker
for macrophages/microglia. There was no MCPIP1 ex-
pression co-localizing in the microglia, as seen by
merging of the immunostained images obtained with
antibodies against MCPIP1 and macrophage/microglia
antigen CD11b (Figure 3i). These observations indicate
that MCPIP1 protein is upregulated mainly in neurons
and to a lesser extent in astrocytes in the mice brain
after EA pretreatment.
Measurement of MCP-1 and MCPIP1 at later time points
after EA pretreatment
To determine the expression of MCP-1 after EA pre-
treatment we measured MCP-1 mRNA level in mice
brain at 3 h, 6 h, and 12 h after EA treatment. The
results showed that the expression levels of MCP-1
had no significant changes after EA pretreatment and
that MCPIP1 mRNA decreased at later time points
(Figure 4).
Loss of EA pretreatment-induced tolerance to ischemic
stroke by MCPIP1 deficiency
We examined the effects of EA pretreatment on ische-
mic brain infarction. MCPIP1 knockout or wild-type mice
were pretreated with EA for two days as described in
methods and these mice were subjected to MCAO 24 h
after the end of the last EA pretreatment. The brain infarct
size was assessed with TTC staining 48 h after MCAO
and the results showed that the infarct size of EA-
pretreated wild-type mice was significantly reduced com-
pared to that of control. (35.1 ± 5.7% versus 18.2 ± 4.3%,
Figure 5A, B). MCPIP1 knockout mice failed to evoke EA
pretreatment-induced tolerance compared with that of the
control MCPIP1 knockout group without EA treatment
(43.2 ± 7.3% versus 47.6 ± 6.9%, Figure 5A, B). There was
no significant difference in brain infarct size between EA-
pretreated and control in MCPIP1 knockout mice. The
neurological functions of mice were determined and
the results showed that the neurological scores of EA-
pretreated wild-type mice were significantly improved
compared to that of control. In MCPIP1-deficient
mice, there was no significant difference in neuro-
logical deficits between the EA-pretreated and the con-
trol group (Figure 6).
Proinflammatory cytokine expression
We examined the expression of proinflammatory cyto-
kine transcript in the ischemic brain of the wild-type
and MCPIP1 knockout mice with or without EA pre-
treatment after MCAO. The results showed that the ex-
pression levels of TNF-α, IL-1β, IL-6 and MCP-1 mRNA
were significantly elevated in shams in MCPIP1 knock-
out mice than that of wild type (for example TNF-α: 1 ±
0.27 versus 2.8 ± 0.35) and that the expression levels of
TNF-α, IL-1β, IL-6 and MCP-1 were significantly re-
duced at 24 h after MCAO in EA-pretreated wild-type
mice compared to that of non-EA control. In the
MCPIP1-deficient mice, there was no significant differ-
ence in proinflammatory cytokine expression between
Figure 8 Leukocyte infiltration in the cerebral cortex. Reduction of leukocyte infiltration in ischemic cerebral cortex by EA pretreatment in
wild-type but not in MCPIP1 knockout mice. (A) Immunostaining of leukocyte in the cortex using anti CD45 antibody. (B) Qualification of CD45
fluorescence intensity. Each plot is an average of four animals each group. (Magnification 600X.) EA, electroacupuncture; MCPIP1, monocyte
chemotactic protein-induced protein 1.
Jin et al. Journal of Neuroinflammation 2013, 10:63 Page 7 of 11
http://www.jneuroinflammation.com/content/10/1/63
the EA-pretreated and the control group without EA
treatment (Figure 7).
Leukocyte infiltration in cerebral brain
To determine the effect of MCPIP1 on leukocyte infiltra-
tion after stroke, we examined leukocyte infiltration in
the cerebral cortex in the wild-type and MCPIP1 knock-
out mice at 48 h after brain ischemia/reperfusion. As
illustrated in Figure 8, leukocyte infiltration, visualized
with CD45 antibody that specially binds to leukocyte
common antigen, was significantly reduced at 48 h after
MCAO in EA-pretreated wild-type mice compared to
that of non-EA control. In the MCPIP1-deficient mice,
there was no significant difference in leukocyte infiltra-
tion between the EA-pretreated and the control group
without EA treatment (Figure 8).
Activation of NF-κB signaling pathway
Since activation of the nuclear factor-kappa B (NF-κB)
signaling pathway is involved in the production of
proinflammatory cytokines, we tested whether EA pre-
treatment affect NF-κB activation. The results showed
that phosphorylation of p65 was significantly reduced at
24 h after MCAO in EA-pretreated wild-type mice com-
pared to that of control. In MCPIP1-deficient mice,
there was no significant difference in p65 phosphoryl-
ation level between the EA-pretreated and the control
group without EA treatment (Figure 9).
Discussion
Electroacupuncture is a traditional therapy that has been
widely applied for treatment of ischemic stroke and
many studies have shown that acute EA has therapeutic
benefits for stroke patients and in animal stroke models
[12,33-38]. Many investigators used five sessions of EA
while the others used a single session of EA [29]. In our
preliminary experiments, we found that two sessions of
EA pretreatment can significantly induce the expression
of the MCPIP1 gene and also provide more stable
neuroprotective effects on brain infarct volume than that
of one session of EA. Therefore, we selected the option
of two sessions of EA pretreatment for this study.
Although it has been known that EA pretreatment can
induce significant tolerance to ischemic brain injury
[13,39-42] and inhibit inflammatory responses, such as
activation of NF-κB and proinflammatory cytokine gen-
eration [21,40], the molecular mechanisms that contrib-
ute to brain ischemia tolerance by EA pretreatment are
not well understood. The present study is the first to
examine the role of MCPIP1 in EA pretreatment-
induced cerebral ischemic tolerance. We found that
MCPIP1 is significantly induced in mouse brain by EA
treatment. This induction of MCPIP1 by the EA treat-
ment was brain-specific as other organs did not manifest
such induction. We noticed that there was larger ische-
mic brain infarct area in MCPIP1-deficient mice com-
pared to that of wild type. In our previous study, we
found higher mortality in MCPIP1 knockout mice
subjected to focal brain ischemia/reperfusion injury than
that of wild type. This finding suggests that MCPIP1-
deficient mice are more sensitive to ischemic brain
injury than wild type. In the present study, we found
that there was significant loss of EA pretreatment-
induced ischemic brain tolerance in MCPIP1-deficient
mice. These results indicate at least two possibilities:
one is that MCPIP1 indeed participates in the EA
pretreatment-induced ischemic tolerance; the other is
that the preexisting conditions of the MCPIP1 knockout
mice may be too detrimental to be overcome by EA pre-
treatment. Considering the other experimental results in
this study, including that MCPIP1 can be significantly
induced by EA treatment in the brain, and that MCPIP1
has been identified as an important inducible anti-
Figure 9 Inhibition of NF-κB activation in the ischemic brain by
EA treatment in the wild-type, but not in MCPIP1 knockout
mice. Activation of NF-κB signaling pathway. A representative
western blot shows protein levels of p65 phosphorylation. The
phosphorylation of p65 was significantly reduced at 24 h after
MCAO in EA-pretreated wild-type mice compared to that of control.
In MCPIP1-deficient mice, there was no significant difference in p65
phosphorylation level between the EA-pretreated and the control
group without EA treatment. Densitometric analysis was used to
quantify phospho-p65 protein levels versus total p65 in three
independent western blots and the data are expressed as the
normalized folds with respect to sham. Values represent mean ± SD.
EA, electroacupuncture; MCAO, middle cerebral artery occlusion;
MCPIP1, monocyte chemotactic protein-induced protein 1; NF-κB,
nuclear factor-kappa B; SD, standard deviation.
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inflammatory regulator in stroke pathophysiology [28], it
would appear more likely to that MCPIP1 actually par-
ticipates in the EA pretreatment-induced ischemic toler-
ance. The role of MCPIP1 as a mediator of EA-induced
tolerance of ischemic brain damage is consistent with
the well-known role of inflammatory processes in the
brain damage in ischemic stroke [4] and the anti-
inflammatory properties of MCPIP1 [24,25]. Thus, we
conclude that MCPIP1 is involved in EA pretreatment-
induced delayed ischemic stroke tolerance by its anti-
inflammatory activities.
It is well known that proinflammatory gene expression
and leukocyte infiltration contribute to stroke damage
[5,43,44]. During ischemia, cytokines, such as TNF-α,
IL-1β, IL-6, and chemokines such as cytokine-induced
neutrophil chemoattractant (CINC) and MCP-1 are pro-
duced by a variety of activated cell types, including
endothelial cells, microglia, astrocytes and neurons [46].
EA pretreatment can induce significant tolerance to is-
chemic brain injury and inhibit inflammatory responses
such as activation of NF-κB and proinflammatory cyto-
kine generation. However, the molecular mechanisms
that mediate the beneficial effects in EA pretreatment-
induced ischemic tolerance remains poorly understood.
In this study, we observed that TNF-α, IL-1β, IL-6 and
MCP-1 expressions were significantly reduced at 24 h
after MCAO in EA-pretreated wild-type mice compared
to that of control. In MCPIP1-deficient mice, there was
no significant difference in proinflammatory cytokine
expression between the EA pretreatment and the control
group without EA treatment. It has been demonstrated
that leukocyte infiltration into the ischemic brain in
transient MCAO models is prominent and that anti-
leukocyte strategies (including anti-adhesion molecule
strategies) have generally proven to be significantly ef-
fective in animal stroke models of transient ischemia. In
the present study, we observed that the infiltration of
leukocytes was significantly reduced at 48 h after MCAO
in EA-pretreated wild-type mice compared to that of
non-EA control mice. In the MCPIP1-deficient mice,
there was no significant difference in leukocyte infiltra-
tion between the EA-pretreated and the control group
without EA treatment.
It has been established that EA pretreatment can
induce ischemic tolerance. Less well studied is what
mediates such beneficial tolerance in the precon-
ditioning process. If this mediator is absent, EA
pretreatment-induced tolerance would not occur. We
conclude that MCPIP1 is such a mediator that is
involved in EA pretreatment-induced tolerance. When
MCPIP1 is deficient, EA-induced tolerance is reduced
and results in higher level of proinflammatory cyto-
kines and greater infiltration of leukocytes in ischemic
brain.
How MCPIP1 regulates these inflammatory cytokine
responses remains to be fully elucidated. It has been
reported that MCPIP1 might be functioning as an RNase
to promote the degradation of mRNA for inflammatory
cytokines, such as IL-6 and IL-1β [25]. We have found
that MCPIP1 can also act as a deubiquitinase to nega-
tively regulate NF-κB signaling by targeting TNF recep-
tor-associated factors (TRAFs) [24,45], which suggests
that MCPIP1 may control inflammatory response by
multiple mechanisms. Activation of NF-κB signaling
pathways leads to inflammatory cytokine production. In
this study, we found that that phosphorylation of p65
was significantly reduced at 24 h after MCAO in EA-
pretreated wild-type mice compared to that of control.
In MCPIP1-deficient mice, there was no significant
difference in p65 phosphorylation level between the
EA-pretreated and the control group without EA treat-
ment. Our study suggests that increased activation of
NF-κB signaling pathways in MCPIP1 knockout mice
leads to increased proinflammatory cytokine production.
The main purpose of this study was to determine the
participation of the MCPIP1 gene expression in EA
pretreatment-induced ischemic stroke tolerance. Whe-
ther EA treatment after stroke provides therapeutic ben-
efits, and if MCPIP1 might be involved in such possible
benefits, require exploration. Since EA-induced MCPIP1
expression is mostly in the neurons, mice with neu-
ron-specific MCPIP1 deficiency might provide a suitable
model to explore the role of MCPIP1 in stroke-induced
damage. Efforts are under way to explore such
possibilities.
Conclusions
Based on the data, we conclude that MCPIP1 induction
mediates the EA-induced delayed tolerance of ischemic
brain injury and that MCPIP1 is involved in EA
pretreatment-induced brain ischemia tolerance.
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